

CORRECTION

Open Access

# Correction to: Butyrophilin-like 9 expression is associated with outcome in lung adenocarcinoma



Weishuang Ma<sup>1,2†</sup>, Jiaming Liang<sup>3†</sup>, Junjian Mo<sup>1†</sup>, Siyuan Zhang<sup>1†</sup>, Ningdong Hu<sup>4</sup>, Dongbo Tian<sup>1\*</sup> and Zisheng Chen<sup>1\*</sup>

**Correction to: BMC Cancer 21, 1096 (2021)**

<https://doi.org/10.1186/s12885-021-08790-9>

Following publication of the original article [1], the authors identified an error in Fig. 2. The gene *BTN3A1* has Chinese text characters, and *BTN3A2*, *BTN3A3*, *BTNL2*, *BTNL3*, *BTNL8*, *BTNL9*, *BTNL10*, and *SKINTL* are not marked.

The corrected Fig. 2 is given below and the original article [1] has been corrected.

#### Author details

<sup>1</sup>Department of Respiratory Medicine, The Sixth Affiliated Hospital of Guangzhou Medical University Qingyuan People's Hospital, Qingyuan, China.

<sup>2</sup>Zhouxin Community Health Service, Qingcheng District, Qingyuan, China.

<sup>3</sup>State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, Guangzhou, China. <sup>4</sup>Department of Thoracic Surgery, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China.

Published online: 26 October 2021

#### Reference

1. Ma W, Liang J, Mo J, et al. Butyrophilin-like 9 expression is associated with outcome in lung adenocarcinoma. *BMC Cancer*. 2021;21:1096. <https://doi.org/10.1186/s12885-021-08790-9>.

The original article can be found online at <https://doi.org/10.1186/s12885-021-08790-9>.

\* Correspondence: [2682105044@qq.com](mailto:2682105044@qq.com); [502463784@qq.com](mailto:502463784@qq.com)

<sup>†</sup>Weishuang Ma, Jiaming Liang, Junjian Mo and Siyuan Zhang contributed equally to this work.

<sup>1</sup>Department of Respiratory Medicine, The Sixth Affiliated Hospital of Guangzhou Medical University Qingyuan People's Hospital, Qingyuan, China  
Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.




Fig. 2 (See legend on next page.)

(See figure on previous page.)

**Fig. 2** *BTNL9* Expression and prognosis in LUAD. **A** *BTNL9* expression panel in LUAD tissues compared with adjacent tissues in GEPIA database. **B** Correlation between *BTNL8* and *BTNL9* expression and LUAD clinical stages, N stage, and *p53* mutation in the UALCAN database (*BTNL8* expression compared with LUAD clinical stages (Normal-vs-Stage1,  $P = 1.01E-04$ ; Normal-vs-Stage2,  $P = 7.08E-03$ ; Normal-vs-Stage3,  $P = 1.36E-04$ ; Normal-vs-Stage4,  $P = 1.78E-08$ ), N stage (Normal-vs-N0,  $P = 6.56E-04$ ; Normal-vs-N1,  $P = 8.27E-10$ ; Normal-vs-N2,  $P = 5.96E-04$ ; Normal-vs-N3,  $P = 1.97E-10$ ; N0-vs-N1,  $P = 3.27E-03$ ; N0-vs-N3,  $P = 6.79E-04$ ), and *p53* status (Normal-vs-T P53-Mutant,  $P = 1.27E-06$ ; Normal-vs-T P53-NonMutant,  $P = 1.80E-03$ ). *BTNL9* expression comparison with LUAD clinical stages (Normal-vs-Stage1,  $P = 1.21E-12$ ; Normal-vs-Stage2,  $P = 3.60E-13$ ; Normal-vs-Stage3,  $P = 2.40E-12$ ; Normal-vs-Stage4,  $P = 2.25E-12$ ), N stage (Normal-vs-N0,  $P = 1.08E-12$ ; Normal-vs-N1,  $P = 1.85E-12$ ; Normal-vs-N2,  $P = 1.02E-12$ ; Normal-vs-N3,  $P = 1.67E-12$ ; N0-vs-N1,  $P = 1.02E-03$ ; N2-vs-N3,  $P = 3.01E-02$ ), and *p53* status (Normal-vs-T P53-Mutant,  $P = 1.85E-12$ ; Normal-vs-T P53-NonMutant,  $P = 4.10E-12$ ; T P53-Mutant-vs-T P53-NonMutant,  $P = 1.77E-04$ )). **C** Correlation between *BTNL8* and *BTNL9* expression with overall survival of LUAD using GEPIA database. **D** Correlation between *BTNL9* expression and LUAD overall survival using OncoLnc, UALCAN, and KM plotter databases. \*:  $P$ -value < 0.05; \*\*:  $P$ -value < 0.01; \*\*\*:  $P$ -value < 0.001